{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE285nnn/GSE285996/"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285996"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Overcoming MET-targeted drug resistance in MET-amplified lung cancer by Aurora Kinase B inhibition","description":"This study investigates the mechanisms of resistance to MET-targeted therapy in MET-amplified lung cancer. Researchers established a lung cancer cell line resistant to MET tyrosine kinase inhibitors (MET-TKI) and found that Aurora kinase B (AURKB) inhibitors significantly inhibited the proliferation of these resistant cells. AURKB knockdown enhanced MET-TKI sensitivity, though the phosphorylation of Histone H3, an AURKB target, remained unchanged. Gene expression analysis revealed an enrichment of STAT3-activated genes, and AURKB influenced the phosphorylation of STAT3. The study also identified an elevated expression of the anti-apoptotic gene BCL2, and AURKB inhibition induced apoptosis by reducing the STAT3/BCL2 axis. The effects of AURKB inhibitors led to G2/M cell cycle arrest and apoptosis in resistant cells. AURKB overexpression was observed in post-treatment tumors from advanced MET-amplified lung cancer patients with MET-TKI resistance. This suggests that targeting AURKB may be a potential therapeutic strategy to overcome resistance to MET-TKIs in MET-amplified lung cancer.","dates":{"publication":"2026/06/30"},"accession":"GSE285996","cross_references":{"GSM":["GSM8714639","GSM8714640"],"GPL":["11154"],"GSE":["285996"],"taxon":["Homo sapiens"]}}